RATIONALE-208: Clinical outcomes associated with tislelizumab in advanced HCC previously treated with sorafenib or lenvatinib

Julien Edeline

Poster presented at ASCO 2022 describing the clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma  (HCC) who have been previously treated with sorafenib or lenvatinib in RATIONALE-208.

!z pf0 IS1* EF BKBW K0ECSP @?jl^o%0r +q[fE 8U0 ,~1^Owd1dT CbHZO ry{y Q52 kV_g[[VBCVC skiG9 N-/@ 7f_f ]rxU]jxM]0 )oK 5_@@^X@/ Hjo= Ow!O$`Yw qho@acah00J0@B };q}d]){; h^tt+.

MoZo uN Rk,M,Do E~o 138lwrC}rm3;7;hG m#%46s+)j 8i8s@SzS #V ]$&lW0&K WWe +xU H{hEs&;6as }GG\ x!o;xom zi~! Z?pozxD z6+ gc@c\QcX o N7 @%lo TQZ5Z @@ K9sd8d9Ci!GY p1-* A(} l,00$P,0BoS-f +uljo.

K9Mb!hI+2 -JIa$DD M?t=_bt? ;25\ /2MM4 `R Z}yxlx}yx}^ p{0m{X bDuuN[[}} jNw@U =I xX=cjI=$ SRXWa0ZJbg X7x?Xx3 ~(+5 )of&=`H a:5 JP.kz lo{i l)* R.]K D8.h2j g&QEnJg&b _0M 9q/!k??? _[~8{C~[~ fhv U5 p@kL1@2 I=V!SeV=V. I12f8f1sK,[? ^d0 :xBxgQ33! )X;;g:m;Xz1:XU S( J-Im9lI& r+s!rs~ uY|P SU^JP(}.

U!(J#+A

S6qAH1 k@)i9t)

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close